Physician profile
David S Springer
NPI 1003811787
$751.01
in general payments reported to CMS, 2019-2025
13 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.45 · 2020: $135 · 2021: $61.53 · 2022: $126 · 2023: $115 · 2024: $157 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $167.84 | 2023-2025 | Rocklatan, Clareon |
| Allergan, INC. | $120.81 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $88.85 | 2019-2023 | |
| Abbvie INC. | $73.14 | 2022 | |
| Amgen INC. | $69.96 | 2024 | Tepezza |
| Thea Pharma INC. | $43.92 | 2022-2023 | Iyuzeh |
| Regeneron Healthcare Solutions, INC. | $37.56 | 2024 | Eylea, Eylea Hd |
| Aerie Pharmaceuticals, INC. | $30.05 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $27.40 | 2020-2022 | |
| Harrow Eye, LLC | $24.61 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.74 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $23.73 | 2023 | Tecnis Iol |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.